Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Nakamura

Showing results (121-130 of 127) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 127 results.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 23, 2023
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched studySatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Immunotherapy|May 16, 2023
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumabSatoru Taguchi, Taketo Kawai, Sebastiano Buti, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 23, 2022
Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020)Satoru Taguchi, Taketo Kawai, Tohru Nakagawa, et al.
Neurobiology of Aging|April 18, 2002
Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study groupMikio Shoji, Etsuro Matsubara, Tetsuro Murakami, et al.
Japanese Journal of Clinical Oncology|July 9, 2026
Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world studyIbuki Tsuru, Satoru Taguchi, Ryo Tanaka, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 31, 2015
Na, K-ATPase α3 is a death target of Alzheimer patient amyloid-β assemblyTakayuki Ohnishi, Masako Yanazawa, Tomoya Sasahara, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 22, 2024
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Pageof 13

Showing results (121-130 of 127) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 127 results.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 23, 2023
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched studySatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Immunotherapy|May 16, 2023
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumabSatoru Taguchi, Taketo Kawai, Sebastiano Buti, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 23, 2022
Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020)Satoru Taguchi, Taketo Kawai, Tohru Nakagawa, et al.
Neurobiology of Aging|April 18, 2002
Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study groupMikio Shoji, Etsuro Matsubara, Tetsuro Murakami, et al.
Japanese Journal of Clinical Oncology|July 9, 2026
Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world studyIbuki Tsuru, Satoru Taguchi, Ryo Tanaka, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 31, 2015
Na, K-ATPase α3 is a death target of Alzheimer patient amyloid-β assemblyTakayuki Ohnishi, Masako Yanazawa, Tomoya Sasahara, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 22, 2024
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Pageof 13